Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Clackson

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Blood|July 17, 2004
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CMLThomas O'Hare, Roy Pollock, Eric P Stoffregen, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2008
Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitorsYihan Wang, William C Shakespeare, Wei-Sheng Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2018
Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical TrialsD Ross Camidge, Dong-Wan Kim, Marcello Tiseo, et al.
Blood|November 26, 2015
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsMichael W Deininger, J Graeme Hodgson, Neil P Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical ModelsSen Zhang, Rana Anjum, Rachel Squillace, et al.
Journal of Medicinal Chemistry|January 11, 2013
Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitorsAnna Kohlmann, Stephan G Zech, Feng Li, et al.
Journal of Medicinal Chemistry|July 4, 2009
9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluationWei-Sheng Huang, Xiaotian Zhu, Yihan Wang, et al.
Cancer Discovery|February 26, 2021
Mobocertinib (TAK-788): A Targeted Inhibitor of <i>EGFR</i> Exon 20 Insertion Mutants in Non-Small Cell Lung CancerFrancois Gonzalvez, Sylvie Vincent, Theresa E Baker, et al.
Bioorganic & Medicinal Chemistry Letters|May 13, 2011
Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutantMathew Thomas, Wei-Sheng Huang, David Wen, et al.
Cancer Cell|November 3, 2009
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistanceThomas O'Hare, William C Shakespeare, Xiaotian Zhu, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Blood|July 17, 2004
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CMLThomas O'Hare, Roy Pollock, Eric P Stoffregen, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2008
Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitorsYihan Wang, William C Shakespeare, Wei-Sheng Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2018
Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical TrialsD Ross Camidge, Dong-Wan Kim, Marcello Tiseo, et al.
Blood|November 26, 2015
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsMichael W Deininger, J Graeme Hodgson, Neil P Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical ModelsSen Zhang, Rana Anjum, Rachel Squillace, et al.
Journal of Medicinal Chemistry|January 11, 2013
Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitorsAnna Kohlmann, Stephan G Zech, Feng Li, et al.
Journal of Medicinal Chemistry|July 4, 2009
9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluationWei-Sheng Huang, Xiaotian Zhu, Yihan Wang, et al.
Cancer Discovery|February 26, 2021
Mobocertinib (TAK-788): A Targeted Inhibitor of <i>EGFR</i> Exon 20 Insertion Mutants in Non-Small Cell Lung CancerFrancois Gonzalvez, Sylvie Vincent, Theresa E Baker, et al.
Bioorganic & Medicinal Chemistry Letters|May 13, 2011
Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutantMathew Thomas, Wei-Sheng Huang, David Wen, et al.
Cancer Cell|November 3, 2009
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistanceThomas O'Hare, William C Shakespeare, Xiaotian Zhu, et al.
Pageof 6